BioCentury
ARTICLE | Company News

Sanofi's Dupixent misses sales estimates, Regeneron slips

April 27, 2018 7:07 PM UTC

Sanofi (Euronext:SAN; NYSE:SNY) reported 1Q18 earnings, including sales of atopic dermatitis drug Dupixent dupilumab that missed estimates.

The company's partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) slid $10.92 to $313.05 on the news Friday, shedding nearly $1.2 billion in market cap. ...